Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of TPN-101 in C9ORF72 ALS/FTD
NL-OMON52346Phase 2Withdrawn
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) comparing TPN-101 with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Oct 2021; status: withdrawn.
02
Drugs
censavudine
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON52346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52346.